BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 26, 2025
See today's BioWorld
Home
» Opting for Nasdaq, I-Mab files for $100M IPO in U.S.
To read the full story,
subscribe
or
sign in
.
Opting for Nasdaq, I-Mab files for $100M IPO in U.S.
Oct. 31, 2019
By
David Ho
HO
NG KONG – Shanghai-based
I-Mab Biopharma Co. Ltd.
has filed for an IPO in the U.S., seeking to raise up to $100 million.
BioWorld
Financings
